Metabolic Profiling of Patient Cell Lines for ASD Phenotype 1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for autism spectrum disorder (ASD) are inadequate in identifying specific subgroups for personalized treatment due to genetic and phenotypic heterogeneity, and there is a need for a laboratory-based method to diagnose a specific subtype, ASD Phenotype 1, characterized by Nrf2 pathway dysregulation.
Innovation Solution
A method involving patient-specific cell lines to assess energy production capacity in the presence and absence of carbon sources and Nrf2 activators, comparing it to typically developing controls, to diagnose ASD Phenotype 1 and evaluate therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If behavioral based diagnostic approaches are used for ASD, then a broad diagnostic coverage is achieved, but the ability to classify patients by molecular and genetic alterations is insufficient
Solution Approach 1:
The patent segments the homogeneous ASD diagnostic category into distinct molecular subtypes (ASD1 and ASD2) based on metabolic profiling. By dividing patients into subgroups with different metabolic characteristics (e.g., impaired oxidative phosphorylation in ASD1 vs. impaired glycolysis in ASD2), the method achieves both broad diagnostic coverage and precise molecular classification simultaneously.
Solution Approach 2:
The patent introduces metabolic profiling as an intermediary diagnostic tool that bridges behavioral observation and molecular genetics. Instead of directly measuring genetic alterations, the method uses metabolic phenotypes (energy production capacity, substrate utilization) as intermediate markers that reflect underlying molecular and genetic alterations, thereby achieving precise classification without requiring direct genetic measurement.
2Measurement precision
If genetic screening is performed to identify causal factors, then molecular etiology can be determined, but the diagnostic efficiency remains low for idiopathic cases
Solution Approach 1:
The patent replaces the mechanical/genetic screening approach with a metabolic functional assay. Instead of screening for specific genetic mutations (which is time-consuming and has low yield for idiopathic cases), the method measures functional metabolic outputs (energy production, substrate utilization) that directly reflect the operational state of cellular machinery, providing both precision and efficiency.
Solution Approach 2:
The patent changes the diagnostic parameter from genetic composition (static) to metabolic function (dynamic). By measuring energy production capacity under different substrate conditions (e.g., glucose, galactose, pyruvate), the method captures functional alterations that result from genetic and environmental factors, achieving high diagnostic efficiency for idiopathic ASD where genetic causes are not immediately apparent.
3Reliability
If personalized treatment approaches are developed for ASD subtypes, then therapeutic efficacy can be improved, but the complexity of patient classification increases
Solution Approach 1:
The patent applies local quality by identifying specific metabolic defects in different ASD subtypes (oxidative phosphorylation impairment in ASD1, glycolysis impairment in ASD2). This localized metabolic characterization allows for targeted therapeutic interventions specific to each subtype's metabolic weakness, improving therapeutic efficacy while keeping the classification system based on simple metabolic readouts rather than complex multi-parameter systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables efficient identification of ASD Phenotype 1 patients and personalized pharmacological therapy by measuring energy production capacity in patient-specific cell lines, providing a reliable ex vivo diagnostic and therapeutic assessment.
Implementation Method 1
assessing the energy production capacity of patient specific cell lines in presence of various carbon sources of energy
Implementation Method 2
assessing the energy production capacity of patient specific cell lines in presence of various carbon sources of energy
Data Source
AI summary
The invention relates to a method of diagnosing a subtype of autism spectrum disorder (ASD), so called ASD Phenotype 1, by assessing the energy production capacity of patient specific cell lines in presence of various carbon sources of energy and metabolic factors or by assessing the changes in energy production capacity or lack thereof after administration of an Nrf2-inhibitor.